about
Mitochondria in Cancer Energy Metabolism: Culprits or Bystanders?The sweet trap in tumors: aerobic glycolysis and potential targets for therapyMutant p53 Drives Cancer by Subverting Multiple Tumor Suppression PathwaysMutant p53: One, No One, and One Hundred ThousandThe Contrived Mutant p53 Oncogene - Beyond Loss of FunctionsTumor suppressor p53 and its gain-of-function mutants in cancerTumor suppressor p53 and its mutants in cancer metabolismTime and Circumstances: Cancer Cell Metabolism at Various Stages of Disease ProgressionChanging perspective on oncometabolites: from metabolic signature of cancer to tumorigenic and immunosuppressive agentsEmerging Non-Canonical Functions and Regulation by p53: p53 and Stemnessp53 as a Regulator of Lipid Metabolism in CancerDrugging the addict: non-oncogene addiction as a target for cancer therapyThe role of the p53 tumor suppressor in metabolism and diabetesROS homeostasis and metabolism: a critical liaison for cancer therapyGlutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinomaDLC1 is the principal biologically-relevant down-regulated DLC family member in several cancersReprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma.Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling.p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis.Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis.Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.Pontin, a novel interactor of mutant p53 that promotes mutant p53 gain of function.In vivo genetic dissection of tumor growth and the Warburg effectCullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression.Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.Regulation of glycolysis in head and neck squamous cell carcinoma.Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDRSuppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo.LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway.Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.The paradigm of mutant p53-expressing cancer stem cells and drug resistance.
P2860
Q26766062-BFD0A9B4-A341-4B52-B342-699D58D0876EQ26766079-C718A2F0-B606-4131-980A-CA24C96DD73CQ26767396-CE0AE7C4-CD32-42F1-A2E2-2E8C6013901DQ26770576-739E350F-CD0C-4CE5-972D-FB799D8628B8Q26772237-AFBBBC86-E4D7-4BB5-A021-F9AE139CBC41Q27000754-DA706BFA-1DDE-42A9-A2CF-1E0FAF2C3E0DQ27010683-6B8C0FDC-2FD4-4E67-AC54-FAE3FE74F6BCQ28066966-38848B8E-5A0D-411C-85DC-DAB05A9E11E0Q28073524-60867E08-61F4-4C37-A9F5-A9D94AD3D60CQ28077156-D84750F5-8B4F-4BBE-AB41-B8156F567374Q28079393-8290A3D7-36F7-409D-9E08-ED4CD533D4E3Q28079559-1F5FB00B-7FFF-44A7-851B-3070BC5ABF00Q28079903-C77FDB6C-FB65-4E96-9148-F01472DE1CACQ28080316-E4B368B4-C3EC-417F-8EF8-254F206EBF08Q28239503-ADBA4516-2FFD-4DB1-9D30-126F341922D0Q28397799-A1325CD5-9D16-41F4-B55C-F5DDF6CDAAE2Q33917658-1E7F34A3-ABD5-4D0F-A87A-4FDA7C7977B7Q33947130-56174150-0F7C-4BF3-8168-F43F03D302E4Q34482050-5F1B917E-6677-43BC-B2DC-BAD2E4B9ED55Q34619254-698196A6-3446-4B66-8322-405C294D47D8Q34801565-DBC9EF25-8FF0-4679-B74A-32736AAA77B3Q35596889-44B76C57-F636-4EE1-8205-0EB8808FF784Q35742631-A71FCF3A-13F3-43DA-B1E9-5FFD9C1634FFQ35837200-DD090309-A28C-4581-BC2A-F149BEC2DECEQ35958099-93AE09B2-EB17-476C-A534-6F88CC937090Q36032139-07D23A1F-5749-4397-ACDA-41EB6668BD28Q36056465-5A507191-5AFB-485B-ACC6-C52EA4E1E0F5Q36568490-E061D462-326D-432A-99EE-9B4857F40C39Q36579508-6B1101F4-C07C-4D71-9DFC-EFB595829963Q36962411-D9A62588-09E8-4F10-9073-E6486CABA4D9Q36997999-05A953C8-E05C-4975-BF09-F9EFDCC6D69DQ37270331-8BC39DCC-70F3-42DE-8060-9F477F19EFE6Q37343015-6F7E0828-D688-4363-864B-6E04BFC0DDCCQ37565338-C03F794F-B716-4510-AE25-82F28E12BCD3Q37634341-71F05C62-6333-4209-AE15-C281F93E81D4Q37687017-7255E216-ADC7-4E64-BFEF-4BA472B0E31EQ37718416-9DF062AA-4427-44B8-B76E-D1104F5F0D10Q37718451-F8BF81C6-35F3-4F67-B01A-3F7BE21D1D2CQ37740336-0A7F31F1-8B68-40EF-A28F-7EEEAA19E928Q38198487-2C7C5677-3950-4B91-AB0A-859ABD8AECF0
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Tumour-associated mutant p53 drives the Warburg effect
@en
type
label
Tumour-associated mutant p53 drives the Warburg effect
@en
prefLabel
Tumour-associated mutant p53 drives the Warburg effect
@en
P2093
P2860
P356
P1476
Tumour-associated mutant p53 drives the Warburg effect
@en
P2093
Haiyang Yu
Lianxin Liu
Meihua Lin
Xuehui Hong
Yingjian Liang
Yuhan Zhao
Zhaohui Feng
P2860
P2888
P356
10.1038/NCOMMS3935
P407
P577
2013-01-01T00:00:00Z
P5875
P6179
1005948777